Daniel Ritz currently serves as the Chief Scientific Officer at BioVersys AG since November 2025. Prior to this role, Daniel held significant positions at Idorsia Pharmaceuticals Ltd as Senior Director and Senior Group Leader in Biology from June 2017 to October 2025, and at Actelion (now Janssen Pulmonary Hypertension) from June 2005 to June 2017, where multiple leadership roles in Anti-Infectives Biology were undertaken. Earlier experience includes serving as a Senior Research Scientist at Cubist Pharmaceuticals from June 2002 to May 2005 and completing a Postdoctoral Fellowship at Harvard Medical School in the Department of Microbiology and Molecular Genetics between September 1996 and May 2002. Daniel Ritz earned a Dr. sc nat degree in Microbiology and a Dipl Natw in Biochemistry from ETH Zürich.
This person is not in any teams
This person is not in any offices